aTyr Pharma's Phase 3 Efzofitimod Study: Mixed Results and Market Reaction

The Phase 3 EFZO-FIT™ study did not meet its primary endpoint of change from baseline in mean daily oral corticosteroid (OCS) dose at week 48.

52.6% of patients treated with 5.0 mg/kg efzofitimod achieved complete steroid withdrawal at week 48 vs 40.2% on placebo (p=0.0919).

Clinical improvement was observed in the King’s Sarcoidosis Questionnaire (KSQ)-Lung score at week 48 in the 5.0 mg/kg efzofitimod treatment group vs placebo (p=0.0479).

Wall Street analysts have mixed opinions on ATYR, with Wells Fargo raising its target price to $25.00, while Wall Street Zen downgraded the stock to a 'sell' rating.

Primary Endpoint:: The study did not meet its primary endpoint, with the change from baseline in mean daily OCS dose reducing to an average of 2.79 mg for 5.0 mg/kg efzofitimod vs 3.52 mg for placebo (p=0.3313).

Secondary Endpoints:: Despite the failure of the primary endpoint, several secondary endpoints showed positive trends:

A greater proportion of patients achieved complete steroid withdrawal at week 48 with a KSQ-Lung score improvement in the 5.0 mg/kg efzofitimod treatment group (29.5%) vs placebo (14.4%) (p=0.0199).

Clinical improvement in King’s Sarcoidosis Questionnaire (KSQ)-Lung score at week 48 observed in the 5.0 mg/kg efzofitimod treatment group vs placebo (p=0.0479).

On September 14, 2025, aTyr Pharma's stock price increased by 7.5%, reaching a last traded price of $5.66.

Trading volume declined by 43% compared to its average, indicating mixed sentiment among investors.

HC Wainwright reaffirmed a 'buy' rating with a $35.00 price objective.

Wells Fargo & Company raised their price objective on aTyr Pharma from $17.00 to $25.00 and gave the company an 'overweight' rating.

Wall Street Zen downgraded aTyr Pharma from a 'hold' rating to a 'sell' rating.

Investors should closely monitor aTyr Pharma's discussions with the FDA to determine the future development path for efzofitimod.

Consider the mixed analyst ratings and potential risks associated with the drug's uncertain regulatory pathway.

Keep an eye on the company's ongoing EFZO-CONNECT™ study in systemic sclerosis-related ILD, which could provide an alternative pathway for efzofitimod.

Q: What was the primary endpoint of the EFZO-FIT™ study?

Q: Did the study meet its primary endpoint?

Q: What were some of the positive secondary outcomes?

Q: What are analysts' current recommendations for aTyr Pharma?

aTyr Pharma's Phase 3 trial of efzofitimod for pulmonary sarcoidosis yielded mixed results.

The drug failed to meet its primary endpoint but showed promise in secondary outcomes related to steroid withdrawal and lung function.

Market reaction and analyst ratings reflect the uncertainty surrounding the drug's future.

Investors should monitor the company's discussions with the FDA and ongoing studies to assess the potential of efzofitimod.